Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | EVP, President, CDG | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 1,828 |
Ending reported balance
After 2026-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-05 · Exercise / conversion · Acquired 1,027 · Balance 1,530 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 2 · 2026-09-05 · Tax withholding · Disposed 369 · Balance 1,161 Row 3 · 2026-09-06 · Exercise / conversion · Acquired 1,152 · Balance 2,313 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 4 · 2026-09-06 · Tax withholding · Disposed 485 · Balance 1,828 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,313 |
Reported balance
After 2026-09-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-04 · Grant · Acquired 4,313 · Balance 4,313 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,083 |
Reported balance
After 2026-09-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-05 · Exercise / conversion · Disposed 1,027 · Balance 3,083 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,304 |
Reported balance
After 2026-09-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-06 · Exercise / conversion · Disposed 1,152 · Balance 2,304 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,152 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · derivative · entry 7 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,304 Underlying: Bio-Rad A Common Stock · 1,152 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 485 | $386.11 | $187,263.35 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · nonDerivative · entry 4 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,828 Read SEC document |
| September 06, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,152 | $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · nonDerivative · entry 3 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,027 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · derivative · entry 6 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,083 Underlying: Bio-Rad A Common Stock · 1,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 369 | $386.11 | $142,474.59 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · nonDerivative · entry 2 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161 Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,027 | $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · nonDerivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 4,313 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000006 · wk-form4_1788993956.xml · derivative · entry 5 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,313 Underlying: Bio-Rad A Common Stock · 4,313 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. F3 · derivative.expiration_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 19:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 246 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000004 · wk-form4_1785265542.xml · derivative · entry 3 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492 Underlying: Bio-Rad A Common Stock · 246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 19:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 89 | $314.46 | $27,986.94 |
DisclosureSEC source: 0002024911-26-000004 · wk-form4_1785265542.xml · nonDerivative · entry 2 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503 Read SEC document |
| July 25, 2026 Filed Jul 28, 2026 19:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 246 | $0.00 | $0.00 |
DisclosureSEC source: 0002024911-26-000004 · wk-form4_1785265542.xml · nonDerivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| May 11, 2026 Filed May 13, 2026 19:38 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | SaleBio-Rad A Common Stock | 550 | $246.54 | $135,597.00 |
DisclosureSEC source: 0002024911-26-000002 · wk-form4_1778701106.xml · nonDerivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346 Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:21 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,152 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-25-000006 · wk-form4_1757449263.xml · derivative · entry 4 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,456 Underlying: Bio-Rad A Common Stock · 1,152 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:21 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 413 | $295.43 | $122,012.59 |
DisclosureSEC source: 0002024911-25-000006 · wk-form4_1757449263.xml · nonDerivative · entry 2 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896 Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:21 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,152 | $0.00 | $0.00 |
DisclosureSEC source: 0002024911-25-000006 · wk-form4_1757449263.xml · nonDerivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:21 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 4,110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002024911-25-000006 · wk-form4_1757449263.xml · derivative · entry 3 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,110 Underlying: Bio-Rad A Common Stock · 4,110 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:20 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 245 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-036472 · wk-form4_1753824050.xml · derivative · entry 3 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 738 Underlying: Bio-Rad A Common Stock · 245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:20 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 88 | $264.19 | $23,248.72 |
DisclosureSEC source: 0001628280-25-036472 · wk-form4_1753824050.xml · nonDerivative · entry 2 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157 Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:20 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 245 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-036472 · wk-form4_1753824050.xml · nonDerivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:54 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,918 | $0.00 Strike: $256.45 | $0.00 |
DisclosureSEC source: 0001062993-25-004595 · form4.xml · derivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,918 Underlying: Bio-Rad A Common Stock · 2,918 shares Expires 2035-03-03 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 18:30 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 4,608 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016398 · form4.xml · derivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,608 Underlying: Bio-Rad A Common Stock · 4,608 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:04 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 983 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-014126 · form4.xml · derivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 983 Underlying: Bio-Rad A Common Stock · 983 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.